Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, 114, Taiwan.
Molecular Medicine Research Center, Chang Gung University, Taoyuan City, 333, Taiwan.
Parasit Vectors. 2020 Jun 1;13(1):274. doi: 10.1186/s13071-020-04148-5.
Trichomoniasis is the most common non-viral sexually transmitted disease caused by the protozoan parasite Trichomonas vaginalis. Metronidazole (MTZ) is a widely used drug for the treatment of trichomoniasis; however, increased resistance of the parasite to MTZ has emerged as a highly problematic public health issue.
We conducted iTRAQ-based analysis to profile the proteomes of MTZ-sensitive (MTZ-S) and MTZ-resistant (MTZ-R) parasites. STRING and gene set enrichment analysis (GESA) were utilized to explore the protein-protein interaction networks and enriched pathways of the differentially expressed proteins, respectively. Proteins potentially related to MTZ resistance were selected for functional validation.
A total of 3123 proteins were identified from the MTZ-S and MTZ-R proteomes in response to drug treatment. Among the identified proteins, 304 proteins were differentially expressed in the MTZ-R proteome, including 228 upregulated and 76 downregulated proteins. GSEA showed that the amino acid-related metabolism, including arginine, proline, alanine, aspartate, and glutamate are the most upregulated pathways in the MTZ-R proteome, whereas oxidative phosphorylation is the most downregulated pathway. Ten proteins categorized into the gene set of oxidative phosphorylation were ATP synthase subunit-related proteins. Drug resistance was further examined in MTZ-S parasites pretreated with the ATP synthase inhibitors oligomycin and bafilomycin A1, showing enhanced MTZ resistance and potential roles of ATP synthase in drug susceptibility.
We provide novel insights into previously unidentified proteins associated with MTZ resistance, paving the way for future development of new drugs against MTZ-refractory trichomoniasis.
滴虫病是由原生动物寄生虫阴道毛滴虫引起的最常见的非病毒性性传播疾病。甲硝唑(MTZ)是治疗滴虫病的常用药物;然而,寄生虫对 MTZ 的耐药性增加已成为一个高度棘手的公共卫生问题。
我们进行了 iTRAQ 基于分析,以描绘 MTZ 敏感(MTZ-S)和 MTZ 耐药(MTZ-R)寄生虫的蛋白质组。STRING 和基因集富集分析(GESA)分别用于探索差异表达蛋白的蛋白质-蛋白质相互作用网络和富集途径。选择可能与 MTZ 耐药相关的蛋白质进行功能验证。
从 MTZ-S 和 MTZ-R 蛋白质组中鉴定出 3123 种蛋白质,以响应药物治疗。在鉴定的蛋白质中,MTZ-R 蛋白质组中有 304 种蛋白质差异表达,包括 228 种上调和 76 种下调蛋白。GSEA 显示,与氨基酸相关的代谢途径,包括精氨酸、脯氨酸、丙氨酸、天冬氨酸和谷氨酸,是 MTZ-R 蛋白质组中上调最明显的途径,而氧化磷酸化是下调最明显的途径。十个归入氧化磷酸化基因集的蛋白质是 ATP 合酶亚基相关蛋白。在先用 ATP 合酶抑制剂寡霉素和巴弗洛霉素 A1 预处理的 MTZ-S 寄生虫中进一步检查了耐药性,结果显示 MTZ 耐药性增强,ATP 合酶在药物敏感性中可能发挥作用。
我们提供了与 MTZ 耐药性相关的以前未识别蛋白的新见解,为未来开发针对 MTZ 难治性滴虫病的新药铺平了道路。